🍂 Enjoy the Fall Season! 🍂
MindTheDesk

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

General Montana • November 16, 2026 •
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpointRandomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,…
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"Monetize your website or boost your business with Code-Oryx. Join the network today!"
"Cardamom Spices and more to satisfy the tastebuds 100g $14.94"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Network Cable Repairs from $29"
"Adventure is where you chose to go."